Does the media favor ONC or IMVT?

In the previous week, BeOne Medicines had 1 more articles in the media than Immunovant. MarketBeat recorded 3 mentions for BeOne Medicines and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.96 beat BeOne Medicines' score of 0.35 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BeOne Medicines 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is IMVT or MRNA more profitable?

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets Immunovant N/A -65.66% -59.88% Moderna -143.55% -26.64% -19.32%

Does the media refer more to IMVT or MRNA?

In the previous week, Moderna had 14 more articles in the media than Immunovant. MarketBeat recorded 16 mentions for Moderna and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.96 beat Moderna's score of 0.55 indicating that Immunovant is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Moderna 4 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ROIV or IMVT?

In the previous week, Roivant Sciences had 15 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Roivant Sciences and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.96 beat Roivant Sciences' score of 0.56 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Roivant Sciences 8 Very Positive mention(s) 4 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is BNTX or IMVT more profitable?

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Immunovant's return on equity. Company Net Margins Return on Equity Return on Assets BioNTech -44.39% -5.30% -4.62% Immunovant N/A -65.66% -59.88%

Does the media prefer BNTX or IMVT?

In the previous week, BioNTech had 1 more articles in the media than Immunovant. MarketBeat recorded 3 mentions for BioNTech and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.96 beat BioNTech's score of 0.89 indicating that Immunovant is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Immunovant 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Immunovant (IMVT) Competitors

$38.79 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$38.68 -0.11 (-0.29%)

As of 07/2/2026 07:56 PM Eastern

Compare

IMVT vs. SLNO, ONC, MRNA, ROIV, and BNTX

Should you buy Immunovant stock or one of its competitors? MarketBeat compares Immunovant with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Immunovant include Soleno Therapeutics (SLNO), BeOne Medicines (ONC), Moderna (MRNA), Roivant Sciences (ROIV), and BioNTech (BNTX). These companies are all part of the "medical" sector.

How does Immunovant compare to Soleno Therapeutics?

Immunovant (NASDAQ:IMVT) and Soleno Therapeutics (NASDAQ:SLNO) are both mid-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, valuation, institutional ownership, earnings, analyst recommendations, risk, media sentiment and profitability.

Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market. Comparatively, Soleno Therapeutics has a beta of -2.22, suggesting that its share price is 322% less volatile than the broader market.

Immunovant presently has a consensus target price of $39.70, suggesting a potential upside of 2.35%. Soleno Therapeutics has a consensus target price of $76.67, suggesting a potential upside of 44.63%. Given Soleno Therapeutics' higher probable upside, analysts clearly believe Soleno Therapeutics is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Soleno Therapeutics	2 Sell rating(s)	8 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.08

Soleno Therapeutics has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Soleno Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Soleno Therapeutics	$285.01M	9.69	$20.89M	$1.77	29.95

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 97.4% of Soleno Therapeutics shares are owned by institutional investors. 1.8% of Immunovant shares are owned by insiders. Comparatively, 6.4% of Soleno Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Immunovant had 2 more articles in the media than Soleno Therapeutics. MarketBeat recorded 2 mentions for Immunovant and 0 mentions for Soleno Therapeutics. Immunovant's average media sentiment score of 0.96 beat Soleno Therapeutics' score of 0.94 indicating that Immunovant is being referred to more favorably in the media.

Company	Overall Sentiment
Immunovant	Positive
Soleno Therapeutics	Positive

Soleno Therapeutics has a net margin of 33.70% compared to Immunovant's net margin of 0.00%. Soleno Therapeutics' return on equity of 22.85% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Soleno Therapeutics	33.70%	22.85%	18.25%

Summary

Soleno Therapeutics beats Immunovant on 10 of the 15 factors compared between the two stocks.

How does Immunovant compare to BeOne Medicines?

BeOne Medicines (NASDAQ:ONC) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

BeOne Medicines has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market.

BeOne Medicines has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than BeOne Medicines, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BeOne Medicines	$5.34B	6.11	$286.93M	$4.47	66.59
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

In the previous week, BeOne Medicines had 1 more articles in the media than Immunovant. MarketBeat recorded 3 mentions for BeOne Medicines and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.96 beat BeOne Medicines' score of 0.35 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BeOne Medicines	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BeOne Medicines has a net margin of 8.94% compared to Immunovant's net margin of 0.00%. BeOne Medicines' return on equity of 12.06% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BeOne Medicines	8.94%	12.06%	6.69%
Immunovant	N/A	-65.66%	-59.88%

48.6% of BeOne Medicines shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 6.2% of BeOne Medicines shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

BeOne Medicines currently has a consensus price target of $390.00, indicating a potential upside of 31.03%. Immunovant has a consensus price target of $39.70, indicating a potential upside of 2.35%. Given BeOne Medicines' stronger consensus rating and higher probable upside, analysts clearly believe BeOne Medicines is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BeOne Medicines	1 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	2 Strong Buy rating(s)	2.93
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

BeOne Medicines beats Immunovant on 14 of the 16 factors compared between the two stocks.

How does Immunovant compare to Moderna?

Immunovant (NASDAQ:IMVT) and Moderna (NASDAQ:MRNA) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, risk, profitability, analyst recommendations, institutional ownership and media sentiment.

In the previous week, Moderna had 14 more articles in the media than Immunovant. MarketBeat recorded 16 mentions for Moderna and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.96 beat Moderna's score of 0.55 indicating that Immunovant is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Moderna	4 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a net margin of 0.00% compared to Moderna's net margin of -143.55%. Moderna's return on equity of -26.64% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunovant	N/A	-65.66%	-59.88%
Moderna	-143.55%	-26.64%	-19.32%

Immunovant currently has a consensus price target of $39.70, indicating a potential upside of 2.35%. Moderna has a consensus price target of $37.13, indicating a potential downside of 53.44%. Given Immunovant's stronger consensus rating and higher possible upside, analysts plainly believe Immunovant is more favorable than Moderna.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45
Moderna	5 Sell rating(s)	11 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.83

Immunovant has a beta of 0.76, indicating that its share price is 24% less volatile than the broader market. Comparatively, Moderna has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market.

47.1% of Immunovant shares are owned by institutional investors. Comparatively, 75.3% of Moderna shares are owned by institutional investors. 1.8% of Immunovant shares are owned by company insiders. Comparatively, 10.8% of Moderna shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Immunovant has higher earnings, but lower revenue than Moderna. Immunovant is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A
Moderna	$1.94B	16.28	-$2.82B	-$8.15	N/A

Summary

Moderna beats Immunovant on 8 of the 15 factors compared between the two stocks.

How does Immunovant compare to Roivant Sciences?

Roivant Sciences (NASDAQ:ROIV) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, profitability, media sentiment, risk, valuation and earnings.

In the previous week, Roivant Sciences had 15 more articles in the media than Immunovant. MarketBeat recorded 17 mentions for Roivant Sciences and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.96 beat Roivant Sciences' score of 0.56 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Roivant Sciences	8 Very Positive mention(s)	4 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Immunovant has a net margin of 0.00% compared to Roivant Sciences' net margin of -3,629.19%. Roivant Sciences' return on equity of -20.54% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Roivant Sciences	-3,629.19%	-20.54%	-19.43%
Immunovant	N/A	-65.66%	-59.88%

Roivant Sciences has a beta of 1.11, suggesting that its stock price is 11% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its stock price is 24% less volatile than the broader market.

Roivant Sciences currently has a consensus price target of $33.59, suggesting a potential downside of 4.38%. Immunovant has a consensus price target of $39.70, suggesting a potential upside of 2.35%. Given Immunovant's higher probable upside, analysts clearly believe Immunovant is more favorable than Roivant Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Roivant Sciences	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

64.8% of Roivant Sciences shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 10.8% of Roivant Sciences shares are owned by company insiders. Comparatively, 1.8% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Roivant Sciences has higher revenue and earnings than Immunovant. Roivant Sciences is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Roivant Sciences	$8.26M	3,059.07	-$299.77M	-$0.60	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

Summary

Roivant Sciences beats Immunovant on 11 of the 15 factors compared between the two stocks.

How does Immunovant compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Immunovant (NASDAQ:IMVT) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their profitability, earnings, analyst recommendations, valuation, institutional ownership, dividends, risk and media sentiment.

Immunovant has a net margin of 0.00% compared to BioNTech's net margin of -44.39%. BioNTech's return on equity of -5.30% beat Immunovant's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-44.39%	-5.30%	-4.62%
Immunovant	N/A	-65.66%	-59.88%

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 47.1% of Immunovant shares are owned by institutional investors. 19.2% of BioNTech shares are owned by insiders. Comparatively, 1.8% of Immunovant shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Immunovant has lower revenue, but higher earnings than BioNTech. BioNTech is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$3.25B	7.60	-$1.29B	-$5.88	N/A
Immunovant	N/A	N/A	-$505.61M	-$2.78	N/A

BioNTech has a beta of 1.32, suggesting that its share price is 32% more volatile than the broader market. Comparatively, Immunovant has a beta of 0.76, suggesting that its share price is 24% less volatile than the broader market.

In the previous week, BioNTech had 1 more articles in the media than Immunovant. MarketBeat recorded 3 mentions for BioNTech and 2 mentions for Immunovant. Immunovant's average media sentiment score of 0.96 beat BioNTech's score of 0.89 indicating that Immunovant is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Immunovant	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

BioNTech currently has a consensus price target of $129.56, indicating a potential upside of 32.83%. Immunovant has a consensus price target of $39.70, indicating a potential upside of 2.35%. Given BioNTech's stronger consensus rating and higher possible upside, analysts clearly believe BioNTech is more favorable than Immunovant.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Immunovant	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

Summary

BioNTech beats Immunovant on 10 of the 16 factors compared between the two stocks.

Get Immunovant News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding IMVT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

IMVT vs. The Competition

Export

Metric	Immunovant	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.96B	$3.78B	$7.18B	$12.47B
Dividend Yield	N/A	2.16%	2.66%	6.50%
P/E Ratio	-13.95	21.61	28.02	24.70
Price / Sales	N/A	325.90	532.59	97.92
Price / Cash	N/A	147.12	49.26	57.09
Price / Book	9.26	8.66	10.96	6.46
Net Income	-$505.61M	$23.81M	$3.57B	$337.01M
7 Day Performance	-0.15%	3.39%	2.12%	1.69%
1 Month Performance	24.69%	10.81%	5.25%	3.81%
1 Year Performance	130.84%	62.61%	33.29%	23.90%

Immunovant Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
IMVT Immunovant	1.5447 of 5 stars	$38.79 flat	$39.70 +2.3%	+130.8%	$7.96B	N/A	N/A	120	Analyst Forecast
SLNO Soleno Therapeutics	N/A	$53.01 flat	$76.67 +44.6%	N/A	$2.76B	$285.01M	29.95	30
ONC BeOne Medicines	4.6703 of 5 stars	$289.99 +3.6%	$390.00 +34.5%	+21.2%	$30.71B	$5.74B	64.87	12,000	Analyst Forecast
MRNA Moderna	1.168 of 5 stars	$69.70 +3.6%	$37.13 -46.7%	+161.8%	$26.69B	$1.94B	N/A	4,700	Trending News Gap Down
ROIV Roivant Sciences	1.8287 of 5 stars	$34.73 +1.9%	$33.59 -3.3%	+223.9%	$24.51B	$8.26M	N/A	860	Positive News Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:IMVT) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Immunovant (IMVT) Competitors

IMVT vs. SLNO, ONC, MRNA, ROIV, and BNTX

How does Immunovant compare to Soleno Therapeutics?

Summary

How does Immunovant compare to BeOne Medicines?

Summary

How does Immunovant compare to Moderna?

Summary

How does Immunovant compare to Roivant Sciences?

Summary

How does Immunovant compare to BioNTech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Immunovant (IMVT) Competitors

IMVT vs. SLNO, ONC, MRNA, ROIV, and BNTX

How does Immunovant compare to Soleno Therapeutics?

Which has more volatility & risk, IMVT or SLNO?

Do analysts prefer IMVT or SLNO?

Which has higher valuation & earnings, IMVT or SLNO?

Do institutionals & insiders have more ownership in IMVT or SLNO?

Does the media refer more to IMVT or SLNO?

Is IMVT or SLNO more profitable?

Summary

How does Immunovant compare to BeOne Medicines?

Which has more risk & volatility, ONC or IMVT?

Which has higher valuation & earnings, ONC or IMVT?

Does the media favor ONC or IMVT?

Is ONC or IMVT more profitable?

Do insiders & institutionals believe in ONC or IMVT?

Do analysts recommend ONC or IMVT?

Summary

How does Immunovant compare to Moderna?

Does the media refer more to IMVT or MRNA?

Is IMVT or MRNA more profitable?

Do analysts rate IMVT or MRNA?

Which has more risk and volatility, IMVT or MRNA?

Do institutionals and insiders believe in IMVT or MRNA?

Which has preferable earnings and valuation, IMVT or MRNA?

Summary

How does Immunovant compare to Roivant Sciences?

Does the media refer more to ROIV or IMVT?

Is ROIV or IMVT more profitable?

Which has more volatility & risk, ROIV or IMVT?

Do analysts prefer ROIV or IMVT?

Do institutionals & insiders have more ownership in ROIV or IMVT?

Which has higher valuation & earnings, ROIV or IMVT?

Summary

How does Immunovant compare to BioNTech?

Is BNTX or IMVT more profitable?

Do institutionals & insiders believe in BNTX or IMVT?

Which has higher earnings & valuation, BNTX or IMVT?

Which has more risk and volatility, BNTX or IMVT?

Does the media prefer BNTX or IMVT?

Do analysts recommend BNTX or IMVT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

IMVT vs. The Competition

Immunovant Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools